| Phase 15 trials |
|
Phase 1
|
NCT06010901 |
Jan 2024 → Mar 2025 |
colorectal cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT05975645 |
Aug 2023 → Jun 2025 |
hepatocellular carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05451407 |
Aug 2022 → Oct 2023 |
melanoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT05426798 |
Apr 2022 → Sep 2023 |
acute myeloid leukemia |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04623892 |
Dec 2020 → Jul 2021 |
cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05834543 |
May 2023 → Oct 2024 |
esophageal squamous cell carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05783921 |
May 2023 → Aug 2024 |
head and neck squamous cell carcinoma, metastatic squamous cell carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05400876 |
Jun 2022 → May 2023 |
lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT05645315 |
Apr 2022 → Dec 2023 |
neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT05563480 |
Oct 2022 → May 2025 |
nasopharyngeal carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|